Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Fycompa
Perampanel is an antiepileptic drug, specifically an AMPA receptor antagonist, used as adjunctive therapy for the treatment of partial-onset seizures with or without secondary generalization in patients with epilepsy aged 12 years and older. It works by selectively blocking the AMPA subtype of glutamate receptors, which play a key role in the initiation and spread of seizures in the brain.
Adjunctive therapy for partial-onset seizures with or without secondary generalization in patients with epilepsy aged 12 years and older.
Serious neuropsychiatric events including aggression, hostility, irritability, anger, and homicidal ideation and/or behavior have been reported. Monitor patients for unusual changes in behavior or mood.
Outcome:
Decreased perampanel levels
Mechanism:
Induction of CYP3A4
Outcome:
Increased perampanel levels
Mechanism:
Inhibition of UGT enzymes
Outcome:
May decrease efficacy of oral contraceptives
Mechanism:
Induction of CYP3A4
Most likely new formulation: Extended-release formulation (Year 2025, 75% confidence)
Based on current usage trends and clinical trial data, there is a 90% likelihood that perampanel will remain a first-line treatment option for partial-onset seizures.
Anticonvulsant, Antiepileptic
Pyridopyrimidine